775 related articles for article (PubMed ID: 15663544)
1. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
[TBL] [Abstract][Full Text] [Related]
6. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
8. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
9. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
12. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
13. Duration of dialysis and its relationship to dialysis adequacy, anemia management, and serum albumin level.
Rocco MV; Bedinger MR; Milam R; Greer JW; McClellan WM; Frankenfield DL
Am J Kidney Dis; 2001 Oct; 38(4):813-23. PubMed ID: 11576885
[TBL] [Abstract][Full Text] [Related]
14. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
15. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
[TBL] [Abstract][Full Text] [Related]
16. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
17. 2005 Japanese Society for Dialysis Therapy guidelines for vascular access construction and repair for chronic hemodialysis.
Ohira S; Naito H; Amano I; Azuma N; Ikeda K; Kukita K; Goto Y; Sakai S; Shinzato T; Sugimoto T; Takemoto Y; Haruguchi H; Hino I; Hiranaka T; Mizuguchi J; Miyata A; Murotani N;
Ther Apher Dial; 2006 Oct; 10(5):449-62. PubMed ID: 17096701
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
19. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
20. Management of anemia in erythropoietin-resistant hemodialysis patients.
Dar Santos AE; Shalansky KF; Jastrzebski JP
Ann Pharmacother; 2003 Dec; 37(12):1768-73. PubMed ID: 14632604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]